Omeprazol Punkt (Omeprazole)

Omeprazole acts on the gastric acid secretion pathway and is indicated for several acid‑related disorders.

• Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of esophageal irritation.
• Peptic ulcer disease: supports ulcer healing by maintaining a less acidic gastric environment.
• Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with the condition.
• Erosive esophagitis: aids healing of erosive lesions in the esophagus.
• Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates.

• Omeprazole selectively and irreversibly inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By blocking this final step of acid secretion, it markedly reduces both basal and stimulated gastric acid output, allowing the mucosa to heal and symptoms to improve.

Omeprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhea: usually self‑limiting.
• Abdominal pain or discomfort.
• Nausea or vomiting.
• Flatulence or bloating.
• Constipation.

Serious or Rare Side Effects

• Clostridioides difficile‑associated colitis.
• Acute interstitial nephritis.
• Severe allergic reactions such as anaphylaxis.
• Low magnesium levels (hypomagnesemia).
• Fracture risk with long‑term use.
• Vitamin B12 deficiency with prolonged therapy.

When using Omeprazol Punkt, consider the following safety measures:

• Assess renal function: adjust use in severe impairment.
• Review hepatic status: use with caution in liver disease.
• Evaluate need for long‑term therapy: monitor for bone density loss.
• Monitor electrolytes: watch for low magnesium during extended treatment.
• Pregnancy and lactation: use only if clearly needed.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Omeprazole may affect the plasma concentrations of several co‑administered medicines.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk.
• Atorvastatin: increased exposure, higher risk of myopathy.
• Methotrexate: elevated levels, potential toxicity.

Moderate Interactions (Monitor Closely)

• Warfarin: possible increase in INR, monitor coagulation.
• Digoxin: altered absorption, check serum levels.
• HIV protease inhibitors (e.g., ritonavir): reduced efficacy, adjust dosing if needed.